jRCT1080224103CompletedPhase 3
Efficacy and safety of IK-01 for focal cartilage injury and osteochondritis dissecans,Phase 3 study
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Change in IKDC score at 52 weeks after surgery
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Intervention Model
- A Multicenter, Open-label, Randomized, Parallel-group Comparative Study
- Primary Purpose
- Treatment Purpose
Eligibility Criteria
- Ages
- 18age old over to 50age old under (—)
- Sex
- All
Inclusion Criteria
- •(1) Patients with localized traumatic cartilage damage in the knee joint
- •(2) Patients with an IKDC score of less than 60 during screening
- •(3) Patients with an ICRS or Outerbridge classification of III or IV
- •(4) Patients with cartilage damage in the knee joint, with the area of cartilage damage judged to be 2 cm2 or more and 9 cm2 or less
- •(5) Patients who have not received treatment for MF
- •Sub-study,cohort 1
- •In addition to the main study criteria above, patients who meet the following criteria:
- •(1) Patients who received MF treatment more than one year ago at the time of obtaining consent, but still have cartilage damage, or patients who were deemed ineffective in the main study
- •Sub-study,cohort 2
- •(1) Patients with localized osteochondritis dissecans in the knee joint
- •(2) Patients with an IKDC score of less than 60 at the screening stage
- •(3) Patients with Nelson classification of III or IV on MRI images
- •(4) Patients with osteochondritis dissecans with cartilage damage area judged to be 2 cm2 or more and 9 cm2 or less
Exclusion Criteria
- •(1) Patients with a history of treatment with human (autologous) cartilage-derived tissue regenerative medicine products or equivalent investigational products in the affected limb
- •(2) Patients with cartilage damage or osteochondritis dissecans in both knee joints
- •(3) Patients with knee osteoarthritis
- •(4) Patients with two or more cartilage damage sites in one knee joint, or patients with localized cartilage damage requiring treatment in both knee joints
- •(5) Patients with cartilage damage in the opposing joint surfaces
Outcomes
Primary Outcomes
Change in IKDC score at 52 weeks after surgery
Time Frame: 52 weeks after surgery
Change in IKDC score at 52 weeks after surgery (after IK-01 transplantation or MF) compared to preoperative values in patients with traumatic cartilage injury who did not undergo MF
Secondary Outcomes
- Proportion of subjects with increase of 20 or more in IKDC score(52 weeks after surgery)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
A Phase 3study of FF-31501 in meniscus tear patientsjRCT2073220083FUJIFILM Toyama Chemical Co., Ltd18
Completed
Not Applicable
Phase III clinical trial to evaluate the diagnostic accuracy of QFRjRCT2032210032Medis medical imaging systems191
Unknown
Phase 3
KD-357 Phase III Studypreexposure prophylaxis against rabiesJPRN-jRCT2080222145The Chemo-Sero-Therapeutic Research Institute200
Recruiting
Phase 3
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIFCDfocal cortical dysplasia type IIJPRN-jRCT2031230317Kato Mituhiro20
Active, not recruiting
Not Applicable
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIjRCT203123031720